Scholar Rock Holding Corporation (SRRK)
| Market Cap | 5.27B +77.9% |
| Revenue (ttm) | 570,000 |
| Net Income | -413.61M |
| EPS | -3.39 |
| Shares Out | 122.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 623,481 |
| Open | 44.16 |
| Previous Close | 43.16 |
| Day's Range | 42.76 - 44.16 |
| 52-Week Range | 29.35 - 61.76 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 70.44 (+63.04%) |
| Earnings Date | Nov 10, 2026 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or laten... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SRRK stock is "Strong Buy." The 12-month stock price target is $70.44, which is an increase of 63.04% from the latest price.
News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 39,587 shares of its common sto...
Scholar Rock downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Kalpit Patel downgraded Scholar Rock (SRRK) to Peer Perform from Outperform without a price target citing outperformance over the past year.
Scholar Rock reports Q3 EPS (81c), consensus (84c)
Reports Q3 revenue $570,000, consensus $283,670. “The third quarter was a defining period for Scholar Rock (SRRK), marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first…
Scholar Rock to sell Rare Pediatric Disease PRV for $205M
In November, Scholar Rock (SRRK) entered into a definitive agreement to sell its PRV for $205 million. The closing of the PRV transaction is subject to customary closing conditions, including…
Scholar Rock Holding Earnings Call Transcript: Q3 2026
ISEMBYLD’s U.S. launch showed broad, steady early enrollment, while payer and infusion processes are delaying treatment starts. Q3 revenue was $0.6M; a $205M voucher sale and advancing European and Japanese filings strengthen the outlook.
Scholar Rock Holding Earnings release: Q3 2026
Scholar Rock Holding released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Scholar Rock Holding Quarterly report: Q3 2026
Scholar Rock Holding has published its Q3 2026 quarterly earnings report on November 10, 2026.
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open...
Scholar Rock resubmits MAA for apitegromab to the EMA
Scholar Rock (SRRK) announced it has resubmitted the Marketing Authorisation Application, MAA, for apitegromab for the treatment of children and adults with spinal muscular atrophy, SMA, to the Europe...
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock added to Best Ideas List at Wedbush
Wedbush is adding Outperform-rated Scholar Rock (SRRK) to the firm’s Best Ideas List. Wedbush believes the company is uniquely positioned to deliver a durable, derisked commercial ramp in the neuromus...
Scholar Rock price target raised to $77 from $76 at Truist
Truist raised the firm’s price target on Scholar Rock (SRRK) to $77 from $76 and keeps a Buy rating on the shares. The firm notes that its key opinion leader…
Scholar Rock price target raised to $70 from $63 at JPMorgan
JPMorgan raised the firm’s price target on Scholar Rock (SRRK) to $70 from $63 and keeps an Overweight rating on the shares following the FDA approval of Isembyld. The firm…
Scholar Rock says FDA requested pregnancy safety study for Isembyld
Scholar Rock (SRRK) disclosed earlier today on a live audio webcast yesterday announcing the Food and Drug Administration has approved Isembyld, the company’s management stated in error that the FDA…
Scholar Rock Stock (SRRK) Slides Over 7% on an FDA Safety Update
Scholar Rock stock dropped over 7% on Tuesday after an FDA update related to safety terms for approval of ISEMBYLD.
Scholar Rock price target raised to $72 from $65 at Evercore ISI
Evercore ISI raised the firm’s price target on Scholar Rock (SRRK) to $72 from $65 and keeps an Outperform rating on the shares. Approval of Isembyld “marks a significant advancement”…
Scholar Rock price target raised to $70 from $64 at Wedbush
Wedbush raised the firm’s price target on Scholar Rock (SRRK) to $70 from $64 and keeps an Outperform rating on the shares post the company’s update. The firm is revising…
Scholar Rock price target raised to $75 from $60 at Piper Sandler
Piper Sandler analyst Allison Bratzel raised the firm’s price target on Scholar Rock (SRRK) to $75 from $60 and keeps an Overweight rating on the shares. The firm attributes the…
Scholar Rock price target raised to $70 from $65 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $70 from $65 and keeps a Buy rating on the shares following FDA approval of Isembyld. The label…
Barclays downgrades Scholar Rock on valuation after FDA approval
Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval of Isembyld represents a major milestone…
Scholar Rock downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a $58 price target
Scholar Rock price target raised to $65 from $57 at Jefferies
Jefferies analyst Amy Li raised the firm’s price target on Scholar Rock (SRRK) to $65 from $57 and keeps a Buy rating on the shares after the FDA approved apitegromab…
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients with...